FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897073503> ?p ?o ?g. }

• W2897073503 endingPage "1260" @default.
• W2897073503 startingPage "1248" @default.
• W2897073503 abstract "Abstract Purpose: MET exon 14 splice site alterations that cause exon skipping at the mRNA level (METex14) are actionable oncogenic drivers amenable to therapy with MET tyrosine kinase inhibitors (TKI); however, secondary resistance eventually arises in most cases while other tumors display primary resistance. Beyond relatively uncommon on-target MET kinase domain mutations, mechanisms underlying primary and acquired resistance remain unclear. Experimental Design: We examined clinical and genomic data from 113 patients with lung cancer with METex14. MET TKI resistance due to KRAS mutation was functionally evaluated using in vivo and in vitro models. Results: Five of 113 patients (4.4%) with METex14 had concurrent KRAS G12 mutations, a rate of KRAS cooccurrence significantly higher than in other major driver-defined lung cancer subsets. In one patient, the KRAS mutation was acquired post-crizotinib, while the remaining 4 METex14 patients harbored the KRAS mutation prior to MET TKI therapy. Gene set enrichment analysis of transcriptomic data from lung cancers with METex14 revealed preferential activation of the KRAS pathway. Moreover, expression of oncogenic KRAS enhanced MET expression. Using isogenic and patient-derived models, we show that KRAS mutation results in constitutive activation of RAS/ERK signaling and resistance to MET inhibition. Dual inhibition of MET or EGFR/ERBB2 and MEK reduced growth of cell line and xenograft models. Conclusions: KRAS mutation is a recurrent mechanism of primary and secondary resistance to MET TKIs in METex14 lung cancers. Dual inhibition of MET or EGFR/ERBB2 and MEK may represent a potential therapeutic approach in this molecular cohort." @default.
• W2897073503 created "2018-10-26" @default.
• W2897073503 creator A5004111432 @default.
• W2897073503 creator A5004437156 @default.
• W2897073503 creator A5006290236 @default.
• W2897073503 creator A5006697352 @default.
• W2897073503 creator A5019139016 @default.
• W2897073503 creator A5024203424 @default.
• W2897073503 creator A5030479930 @default.
• W2897073503 creator A5035250507 @default.
• W2897073503 creator A5039791495 @default.
• W2897073503 creator A5045785731 @default.
• W2897073503 creator A5046345178 @default.
• W2897073503 creator A5046460245 @default.
• W2897073503 creator A5049524331 @default.
• W2897073503 creator A5053263729 @default.
• W2897073503 creator A5053843638 @default.
• W2897073503 creator A5063199354 @default.
• W2897073503 creator A5074015604 @default.
• W2897073503 creator A5087741076 @default.
• W2897073503 date "2019-02-15" @default.
• W2897073503 modified "2023-10-14" @default.
• W2897073503 title "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer" @default.
• W2897073503 cites W1980497534 @default.
• W2897073503 cites W1998971866 @default.
• W2897073503 cites W2002214314 @default.
• W2897073503 cites W2016146051 @default.
• W2897073503 cites W2016497607 @default.
• W2897073503 cites W2055453661 @default.
• W2897073503 cites W2062109911 @default.
• W2897073503 cites W2062291041 @default.
• W2897073503 cites W2065477010 @default.
• W2897073503 cites W2069421644 @default.
• W2897073503 cites W2077224394 @default.
• W2897073503 cites W2081801534 @default.
• W2897073503 cites W2083077952 @default.
• W2897073503 cites W2089686819 @default.
• W2897073503 cites W2094337993 @default.
• W2897073503 cites W2094481391 @default.
• W2897073503 cites W2096439168 @default.
• W2897073503 cites W2096540669 @default.
• W2897073503 cites W2103110584 @default.
• W2897073503 cites W2111645707 @default.
• W2897073503 cites W2114556798 @default.
• W2897073503 cites W2121262970 @default.
• W2897073503 cites W2130410032 @default.
• W2897073503 cites W2132831751 @default.
• W2897073503 cites W2154149901 @default.
• W2897073503 cites W2159426719 @default.
• W2897073503 cites W2160212814 @default.
• W2897073503 cites W2167270597 @default.
• W2897073503 cites W2169624569 @default.
• W2897073503 cites W2170259414 @default.
• W2897073503 cites W2180481128 @default.
• W2897073503 cites W223909586 @default.
• W2897073503 cites W2320891531 @default.
• W2897073503 cites W2322182993 @default.
• W2897073503 cites W2346079527 @default.
• W2897073503 cites W2413097448 @default.
• W2897073503 cites W2462806586 @default.
• W2897073503 cites W2463567373 @default.
• W2897073503 cites W2466657922 @default.
• W2897073503 cites W2474854223 @default.
• W2897073503 cites W2475363814 @default.
• W2897073503 cites W2521720507 @default.
• W2897073503 cites W2533448509 @default.
• W2897073503 cites W2547499110 @default.
• W2897073503 cites W2552674955 @default.
• W2897073503 cites W2571208503 @default.
• W2897073503 cites W2581592505 @default.
• W2897073503 cites W2591118779 @default.
• W2897073503 cites W2602870799 @default.
• W2897073503 cites W2603411876 @default.
• W2897073503 cites W2607504523 @default.
• W2897073503 cites W2613362156 @default.
• W2897073503 doi "https://doi.org/10.1158/1078-0432.ccr-18-1640" @default.
• W2897073503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6377821" @default.
• W2897073503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30352902" @default.
• W2897073503 hasPublicationYear "2019" @default.
• W2897073503 type Work @default.
• W2897073503 sameAs 2897073503 @default.
• W2897073503 citedByCount "81" @default.
• W2897073503 countsByYear W28970735032018 @default.
• W2897073503 countsByYear W28970735032019 @default.
• W2897073503 countsByYear W28970735032020 @default.
• W2897073503 countsByYear W28970735032021 @default.
• W2897073503 countsByYear W28970735032022 @default.
• W2897073503 countsByYear W28970735032023 @default.
• W2897073503 crossrefType "journal-article" @default.
• W2897073503 hasAuthorship W2897073503A5004111432 @default.
• W2897073503 hasAuthorship W2897073503A5004437156 @default.
• W2897073503 hasAuthorship W2897073503A5006290236 @default.
• W2897073503 hasAuthorship W2897073503A5006697352 @default.
• W2897073503 hasAuthorship W2897073503A5019139016 @default.
• W2897073503 hasAuthorship W2897073503A5024203424 @default.
• W2897073503 hasAuthorship W2897073503A5030479930 @default.
• W2897073503 hasAuthorship W2897073503A5035250507 @default.
• W2897073503 hasAuthorship W2897073503A5039791495 @default.

• next